LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE FOR THE TREATMENT OF FELINE MAMMARY ADENOCARCINOMA - A MULTICENTER RANDOMIZED DOUBLE-BLIND-STUDY

被引：24

作者：

FOX, LE

MACEWEN, EG

KURZMAN, ID

DUBIELZIG, RR

HELFAND, SC

VAIL, DM

KISSEBERTH, W

LONDON, C

MADEWELL, BR

RODRIGUEZ, CO

JEGLUM, KA

ROSENBERG, M

ROSENTHAL, RC

机构：

[1] UNIV WISCONSIN,MADISON,WI

[2] UNIV CALIF DAVIS,DAVIS,CA 95616

[3] VET ONCOL SERV,W CHESTER,PA

[4] VET CANC REFERRAL GRP,LOS ANGELES,CA

[5] VET SPECIALISTS ROCHESTER,ROCHESTER,NY

来源：

CANCER BIOTHERAPY | 1995年 / 10卷 / 02期

关键词：

D O I：

10.1089/cbr.1995.10.125

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty cats with previously untreated histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.

引用

页码：125 / 130

页数：6